Deadly Fungal Infection 'Candida Auris' Spreading In US Rapidly

Contact Counsellor

Last Updated07/02/2024

A deadly fungal infection, Candida auris, is rapidly spreading in the United States.
Despite its rarity, medical experts warn of its high fatality rate, drug resistance, and ease of spread in healthcare settings.

It is an emerging multidrug-resistant yeast (fungus) that represents a global health threat.
Scientists first discovered C. auris in Japan in 2009, since then, it has spread quickly to other countries.
It can cause infections in various parts of the body, including the bloodstream, open wounds, and ears.
The infection poses significant risks, especially for those with weakened immune systems or using medical devices like feeding tubes, breathing tubes, or catheters.

The symptoms vary depending on the site and severity of the infection, and it can be challenging to distinguish from bacterial infections.
Individuals may carry Candida auris without showing symptoms, a condition known as colonization.
Colonized individuals can still spread the fungus to others, making infection control measures crucial in healthcare settings.
It can also spread through contact with contaminated surfaces or equipment.

Infected or colonized patients should be isolated, and caregivers should adhere to strict hygiene protocols.
- It includes wearing gloves and gowns, using disinfectants, and practicing hand hygiene.
Most C. auris infections are treatable with antifungal drugs.
However, some C. auris infections have been resistant to all three main classes of antifungal medications’ often requiring the use of combination therapies.

Candida auris cases have surged worldwide, with a significant increase reported in recent years.
- In 2022, it infected 2,377 people, compared to 53 cases in 2016.
The rapid spread has led the CDC and WHO to designate it as a growing threat to public health, with 1,471 cases reported in 2021 alone.